-SEC Filing
B. Riley Securities Maintains Buy on TG Therapeutics, Raises Price Target to $23
B. Riley Securities analyst Mayank Mamtani maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $17 to $23.
Related Posts
Coinbase Shares Slide Following SEC Lawsuit: Options Market Predicts Further Decline
Coinbase Global, Inc. (NASDAQ: COIN) shares dropped on Tuesday after the SEC sued the company in N.Y. federal court.
Jefferies Downgrades IronNet to Underperform, Lowers Price Target to $1
Jefferies analyst Joseph Gallo downgrades IronNet (NYSE:IRNT) from Hold to Underperform and lowers the price target from $2.25 to $1.
Harpoon Therapeutics Presents Preclinical Results For Novel T Cell Engagers HPN217 And HPN328 At AACR 2023
Preclinical results for HPN328 suggest potential for long-term anti-tumor immunity and durable responses in patients, as well as utility of combining anti-PD-L1 antibodies to enhance anti-tumor